Live Blog

Weak oil, global cues trigger 1,011-pt Sensex slide; financials worst hit

All that happened in the markets today

SI Reporter New Delhi
BSE, NSE, Nifty, Sensex, Stock market
Photo: Kamlesh Pednekar

3 min read Last Updated : Apr 21 2020 | 4:30 PM IST

4:03 PM

MARKET COMMENT | Vinod Nair, Head of Research at Geojit Financial Services

"After the US crude oil crash, Indian markets, in sync with global markets traded negatively, as the extent of the impact of lockdowns and the global slowdown is becoming evident. Corporate earnings have also been impacted by the pandemic related shutdowns. Post earnings management guidance has also not given clear indication about the recovery path. Earnings results will be in focus for the future course of the company business."

3:47 PM

SECTOR WATCH | Here's how sectoral indices on NSE performed today

3:43 PM

MARKET AT CLOSE | Top losers and gainers on the S&P BSE Sensex

3:39 PM

CLOSING BELL

The S&P BSE Sensex ended at 30,636.71, down 1,011 points or over 3 per cent while NSE's Nifty settled at 8,981.45, down 280 points or 3 per cent.

3:29 PM

Dr Reddy's Labs hits over 4-year high, surges 62% from March low

With today’s rally, the share price of Dr Reddy’s Laboratories has surged 62 per cent from its previous month low of Rs 2,498, touched on March 19, 2020 in the intra-day trade. READ MORE  

3:22 PM

BROKERAGE VIEW:: ICICI Securities on Aurobindo Pharma

Whilst four plants continuing to be under USFDA scrutiny [Unit XI has warning letter, Unit VII, Unit I, Unit IX have official action indicated (OAI) status from the USFDA], re-assignment of VAI status for Unit IV despite 14 observations (that too for an injectable plant where cGMP requirements are even more stringent) came in as a huge positive surprise to us. Unit IV is a critical plant for the company, given most of its pending injectables are filed from this plant. Injectable segment is one of the key drivers for the company’s future growth and margins. We expect the US injectable segment to grow at 22% CAGR in FY19-22E to US$385 million. This is likely to provide much needed sentimental boost to the stock, which is getting valued at commodity multiple. The now defunct Sandoz deal also had its share of negative sentiments for having foregone one of the cheapest M&A bargains in the US generics space. While the recent chain of setbacks on the cGMP front will continue to weigh, a positive outcome like this is likely to provide a silver lining to a stock that is available at ~11x FY22E (~30-40% discount to its historical band and ~50% discount to Nifty Pharma). We ascribe a target price of Rs 770 valuing it 13x FY22E EPS of Rs 59.4. We upgrade the stock from HOLD to BUY to incorporate the significant booster.

3:12 PM

NEWS ALERT :: ICICI Bank confirms exposure to Singapore based oil trader

>> We confirm that the Bank, in the normal course of its business, has exposure to the borrower group in question, is taking due steps to protect its interests, and will appropriately reflect the same in its financial statements, as it would do in respect of all its banking exposures. 

(Via BSE Filing)


3:08 PM

NEWS ALERT

3:02 PM

Stocks that hit 52-week low on BSE today

COMPANY PRICE(rs) 52 WK LOW CHG(%)
ADITYA BIR. FAS. 131.00 129.10 -6.26
GE POWER 429.00 416.05 -2.40
INOX LEISURE 219.30 213.00 -1.99
MAH. SEAMLESS 188.75 185.45 -3.08
» More on 52 Week Low

2:58 PM

STOCK ALERT | Bajaj Finance nears 52-week low of Rs 2,083 hit on April 7

-- Stock down 9% at Rs 2,088 on the BSE

2:52 PM

BROKERAGE VIEW:: ICICI Securities on Himadri Speciality Chemical

Building in the prevailing muted demand prospects both domestically as well as globally in its base business and delay in commissioning of new projects, we expect HSCL to clock sales, PAT CAGR of 7.0%, 14.3%, respectively, in FY20E-22E. With a decline in margin profile, return ratios matrix has reduced to ~10% RoE, which significantly limits our ability to assign a higher valuation multiple to HSCL. Consequently, we value HSCL at | 50 i.e. 10x P/E on FY22E EPS of | 5.0. We derive some comfort from consistent CFO generation with controlled leverage on B/S (debt: equity at ~0.3x). We downgrade the stock from BUY to HOLD.

2:48 PM

Contribution to the S&P BSE Sensex's fall today

2:35 PM

Gold can rise further if China diverts some of its forex: Nilesh Shah

Nilesh shah, the MD & CEO of Kotak AMC, is quite optimistic about mutual funds in general even durimg these difficult time. In an interaction with Rajesh Bhayani, he says that investors in systematic investment plans, or SIPs, ought to continue investing as the current market volatility represents an opportunity for averaging out the acquisition cost. But he also warns that this is leverage can be fatal at this moment. READ MORE

2:28 PM

This small-cap company has found its watershed moment in Covid-19 pandemic

“Our agro chemicals business was running in an auto-pilot mode for decades. It was never a cash-churning business. Agriculture in India is monsoon-dependent and a bad monsoon season can easily ruin your business for next two years at least. We were also never in the big league with no patented molecule, but we somehow managed to survive and diversy,” says Dhirendra Dubey, a whole-time director at Kilpest India. READ MORE

2:22 PM

MARKET CHECK | L&T slips 4.5%

Topics :CoronavirusMarketsUS crude oilInfosys MARKET WRAP

First Published: Apr 21 2020 | 7:35 AM IST